Perioperative Treatment in High-risk Resectable Pancreatic Cancer With NALIRIFOX

Exclusion Criteria

• •1. Any other malignancy within 5 years prior to randomization, with the exception of cured in-situ carcinoma or basal cell carcinoma.
• •2. Patients with distant metastases and/or can not complete resection.
• •3. Active, uncontrolled bacterial, viral, or fungal infections that require systemic treatment.
• •4. Active HIV, HBV, HCV infection.
• •5. Combined with uncontrollable systemic diseases (such as unstable angina, myocardial infarction, congestive heart failure, severe unstable ventricular arrhythmia, severe pericardial disease history and other cardiovascular diseases; hypertension \> grade 2 after medication \[CTCAE v5.0\], diabetes, etc.)
• •6. Presence of severe gastrointestinal disease (including active bleeding, \> grade 1 obstruction \[CTCAE v5.0\], or \> grade 1 diarrhea \[CTCAE v5.0\])
• •7. History of allergy or hypersensitivity to drug or any of their excipients.
• •8. Patients who have chemotherapy and surgery contraindications.
• •9. Documented serum albumin ≤3 g/dL
• •10. Use of strong inhibitors or inducers of CYP3A, CYP2C8 and UGT1A1.
• •11. Pregnant or breastfeeding women, or subjects of childbearing age who refuse contraception.
• •12. Participated in other trial within 30 days prior to the first dose of study treatment.
• •13. Patients who are not suitable to participate in this trial for any reason judged by the investigator